Depew, United States
Empire Genomics is a biotechnology company established in 2006 that specializes in developing advanced molecular diagnostics and genomic products. The company's primary focus is on accelerating precision medicine by providing tools for researchers, clinicians, and pharmaceutical companies to better comprehend, diagnose, and treat complex diseases, especially in oncology.
Empire Genomics offers an extensive portfolio of FISH (Fluorescence In Situ Hybridization) probes, ancillary reagents, and custom assay development services. These products play a crucial role in detecting genetic abnormalities essential for diagnosing and monitoring various cancers and genetic disorders, including gene amplifications, deletions, and rearrangements.
Committed to quality and innovation, Empire Genomics rigorously tests its products to meet industry standards, ensuring reliable results. With a global distribution network, the company continues to advance personalized medicine, enabling healthcare providers worldwide to deliver more targeted and effective treatments to patients.
The company secured a $500.00K Debt Financing investment on 26 April 2021.
